A recent study presented at the Annual Scientific Meeting of the British Blood Transfusion Society, held in Brighton, United Kingdom from October 3-5, 2018, sought to determine the impact of introducing biosimilar filgrastim (sold in the United Kingdom as Zarzio) on the number of patients who were able to achieve target CD34 yield in peripheral blood stem cell mobilization (PBCM).
A recent study presented at the Annual Scientific Meeting of the British Blood Transfusion Society, held in Brighton, United Kingdom from October 3-5, 2018, sought to determine the impact of introducing biosimilar filgrastim (sold in the United Kingdom as Zarzio) on the number of patients who were able to achieve target CD34 yield in peripheral blood stem cell mobilization (PBCM).
Data were collected from 52 patients undergoing PBSC collection at a health system in Edinburgh, Scotland, between March 2017 and February 2018. All patients were mobilized with biosimilar filgrastim subcutaneously at a dose of 5 µL/kg beginning after chemomobilization and continuing until PBSC collection was completed. Stem cell collection was initiated when peripheral blood CD34 cells exceeded 15 µL.
Many different disease states were included within the trial, and the indication for stem cell mobilization included patients with non-Hodgkin lymphoma (n = 24, 46%), multiple myeloma (n = 21, 40%), Hodgkin lymphoma (n = 2, 4%), germ cell tumors (n = 5, 10%).
In total, 71% of patients mobilized with biosimilar filgrastim required only 1 leukapheresis procedure, compared with 50% of patients mobilized with the reference. Additionally, 49% of patients who were mobilized with biosimilar filgrastim achieved their target CD34 yield 24 hours after the planned day of first collection.
Researchers found that biosimilar filgrastim was non-inferior to the reference product in terms of achieving CD34 yield. The study’s authors also noted that delaying the first day of collection by 24 hours may result in a more cost-effective and efficient collection process.
The European market has years of experience with biosimilars. In the European Union, there are currently 7 biosimilar filgrastim options on the market. Conversely, in the United States, biosimilars have only been available since 2015. As such, there are only 2 FDA-approved biosimilar filgrastim products on the market to date.
Reference
Elamin FE, Manson, L. Use of biosimilar filgrastim for peripheral blood stem cell mobilization: a single centre experience in UK. Presented at the Annual Scientific Meeting of the British Blood Transfusion Society October 3-5, 2018, United Kingdom. Abstract PO122. onlinelibrary.wiley.com/doi/epdf/10.1111/tme.12558.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.